CHAMBER HILL STRATEGIES for BIOMARIN PHARMACEUTICAL INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues generally related to the Orphan Drug Tax Credit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | Counsel, U.S. House of Representatives, Committee on Energy and Commerce |
| ANNA KATHERINE WEINSTEIN | — |
Health Issues HCR
Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives; drug pricing proposals; access to rare disease and gene therapy drugs, including S. 2543, The Prescription Drug Pricing Reduction Act of 2019, H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, H.R. 19, the Lower Costs, More Cures Act of 2019, H.R. 5882, the GENE Therapy Payment Act, and H.R. 4439, Creating Hope Reauthorization Act; newborn screening and gene panel screening, including, H.R. 2507, the Newborn Screening Saves Lives Reauthorization Act of 2019 and S. 2158, the Newborn Screening Saves Lives Reauthorization Act of 2019; H.R. 4439, Creating Hope Reauthorization Act; and FDA approvals of drugs designed to treat rare diseases; Health care policies in P.L. 116- 123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, the Families First Coronavirus Response Act; P.L. 116-136, the Coronavirus Aid, Relief, and Economic Security Act of CARES Act; P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act; H.R. 6800, the Heroes Act; H.R. 8406, the Heroes Act; Senate Amendment 2652 related to COVID-19 relief; P.L. 116-159, the Continuing Appropriations Act, 2021 and Other Extensions Act; and P.L.116-260, Consolidated Appropriations Act, 2021.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | Counsel, U.S. House of Representatives, Committee on Energy and Commerce |
| ANNA KATHERINE WEINSTEIN | — |
Medicare/Medicaid MMM
Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, and access to rare disease and gene therapy drugs. Policies proposed in 85 FR 37286, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | Counsel, U.S. House of Representatives, Committee on Energy and Commerce |
| ANNA KATHERINE WEINSTEIN | — |
Immigration IMM
H.R. 4225, For the relief of Maria Isabel Bueso Barrera, Alberto Bueso Mendoza, Karla Maria Barrera De Bueso, and Ana Lucia Bueso Barrera, and S. 2612, For the relief of Maria Isabel Bueso Barrera, Alberto Bueso Mendoza, Karla Maria Barrera De Bueso, and Ana Lucia Bueso Barrera.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | Counsel, U.S. House of Representatives, Committee on Energy and Commerce |
| ANNA KATHERINE WEINSTEIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.